Stirling pharmaceutical firm expands city premises to strengthen capacity
A Stirling medicine manufacturing firm have announced an expansion of its production capabilities in Stirling with the purchase of a new building in the city.
Symbiosis Pharmaceutical Services have acquired the new space to double the footprint of the company across the four facilities it operates in Stirling's Castle Business Park.
The move will see the firm increase their capacity by 50 per cent - with the renamed 'Bruce Building' located close to Symbiosis' existing manufacturing cleanrooms, testing laboratories and GMP Warehouse facilities.
READ MORE:Tiny Scots miracle tot born four months early on seaside break goes home after 94 days in hospital
READ MORE:Man arrested over death of West Lothian dad Gary Nicol
It will see Symbiosis safeguard the existing 130 jobs supported in the city - and also create an additional 50 new jobs in the life sciences sector, with the fit-out work implemented over the next three years.
The new manufacturing facility also includes plans for two new cleanroom-based production lines to strengthen the company's ability to support its biotechnology and pharmaceutical clients and the new medicines and therapies being developed.
Symbiosis CEO Colin MacKay said: “By investing £1.75m in the purchase of a 20,000sq/ft building and subsequently equipping it to provide additional world-class sterile manufacturing capacity for our existing and future clients globally represents the next major strategic chapter in the successful and consistently fast-growing trajectory of Symbiosis.
“This step-change in operational capacity, while retaining the organisational and cultural strengths of a fantastic team here at Symbiosis, positions the company for sustained growth and to bring continued added value to both clients and shareholders alike.
“It also represents the latest strategic initiative for Symbiosis following on from the addition of laboratories and the launch of in-house Quality Control (QC) microbiological and analytical testing services last year.
"The expanded manufacturing capacity will support the strategic ambition of the company to further develop its market presence in its key target markets of North America and the E.U.”
"We look forward to the future launch of the new facility and to the exciting times ahead for Symbiosis.